To evaluate the safety and efficacy of Unani medicines( Karafas and Duqu) in the management of Urolithiasis.

Phase 2

Active, not recruiting

• Conditions: Hasal al Kulya wa Masana(Urolithiasis)

• Registration Number: CTRI/2017/08/009407
• Lead Sponsor: Govt Nizamia Tibbi College Hyderabad

Brief Summary

**This study is open, non randomized and****non comparative clinical trial to asses the safety and efficacy of unani medicine Tukmi Karafs(Apium graveolans) and Tukmi Duqu(Peucedanum grande) in patients with HasÄh al-Kulya wa Masana(Urolithiasis).The patients were selected from OPD of Govt. Nizamia General Hospital Charminar. After screening, the 30 patients  of established Urolithiasis were enrolled according to inclusion and exclusion criteria. The patients will be assessed clinically at every two weeks for subjective assessment of general well being and physical examination . The total duration of treatment will be six weeks. Laboratory investigations(Routine and specific)  will be conducted at the initiation and on the completion of the protocol therapy. The drugs selected for trial were identified, authenticated and standardized at Central Research Institute in Unani Medicine(CRIUM) Hyderabad.The drugs will be given to the patients in the powder form in the dosage of 4gm per day in two divided doses.**

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01-05
• Last Update Posted: 2017-06-28

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• 1.Patients with established Sangi Gurda wa Masana (Urolithiasis) proved by radiological or sonological investigations.
• 2.Hematologic and Biochemical parameters within normal limits.
• 3.Patients with normal liver and kidney function.
• 3.Patients willing to continue whole period of trial with their written consent.

Exclusion Criteria

• 1.Patients with impaired liver and kidney function.
• 2.Patients with urolithiasis causing obstruction needing emergency management.
• 3.Patients already on some medication for urolithiasis.
• 4.Pregnant and lactating women.
• 5.Patients unwilling to provide informed consent or abide by the requirements of the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptomatic relief from clinical symptoms of urolithiasis	06 weeks

Secondary Outcome Measures

Name	Time	Method
Reduction in size of stone or expulsion of stone by viewing ultrasonological impression.	06 weeks

Trial Locations

Locations (1)

Govt. Nizamia Tibbi College; 🇮🇳 Hyderabad, ANDHRA PRADESH, India

Govt. Nizamia Tibbi College

🇮🇳Hyderabad, ANDHRA PRADESH, India

Dr Mohd Rafi Thoker

Principal investigator

9622553118

drrafithoker73@gmail.com